Cough relieving, expectorant, asthma relieving, antibacterial, antipyretic

Cough relieving, expectorant, asthma relieving, antibacterial, antipyretic

Cough relieving, expectorant, asthma relieving, antibacterial, antipyretic

Cough relieving, expectorant, asthma relieving, antibacterial, antipyretic

Aminoglycoside antibiotics have a strong antibacterial effect on Mycobacterium tuberculosis, and the minimum inhibitory concentration is generally 0.5mg/ml. It has antibacterial effects on many Gram-negative bacteria such as Escherichia coli, Klebsiella, Proteus, etc., and is also sensitive to Neisseria meningitidis and Neisseria gonorrhoeae. It mainly binds to the 30S subunit of the bacterial ribosome and inhibits the synthesis of bacterial proteins. Combined use can reduce or delay the development of drug resistance.

Aminoglycoside antibiotics have a strong antibacterial effect on Mycobacterium tuberculosis, and the minimum inhibitory concentration is generally 0.5mg/ml; it has antibacterial effects on many Gram-negative bacilli such as Escherichia coli and Klebsiella; Neisseria meningitidis and Neisseria gonorrhoeae are sensitive to this product; it has poor effects on Staphylococcus and other Gram-positive cocci; various groups of streptococci, Pseudomonas aeruginosa and anaerobic bacteria are resistant to this product. Streptomycin mainly binds to the 30S subunit of the bacterial ribosome and inhibits the synthesis of bacterial proteins. Bacteria are very likely to develop drug resistance after contact with streptomycin, and its combined use with other antibacterial drugs or anti-tuberculosis drugs can reduce or delay the development of drug resistance.

It can dilate coronary arteries, increase coronary blood flow, and improve myocardial hypoxia; it can improve acute cardiovascular and cerebrovascular symptoms and ischemic changes in the electrocardiogram; it can inhibit platelet aggregation, reduce blood viscosity, and lower blood lipids.

It can dilate coronary arteries, increase coronary blood flow, and improve myocardial hypoxia; it can improve acute cardiovascular and cerebrovascular symptoms and ischemic changes in the electrocardiogram; it can inhibit platelet aggregation, reduce blood viscosity, and lower blood lipids.

It can dilate coronary arteries, increase coronary blood flow, and improve myocardial hypoxia; it can improve acute cardiovascular and cerebrovascular symptoms and ischemic changes in the electrocardiogram; it can inhibit platelet aggregation, reduce blood viscosity, and lower blood lipids.

This product is a polypeptide complex that has an inhibitory effect on Mycobacterium tuberculosis. The mechanism is not clear yet, but it may be related to the inhibition of bacterial protein synthesis. Bacteria are prone to develop drug resistance when used alone. This product has incomplete cross-resistance with kanamycin and puromycin.